Trial Profile
Phase II clinical trial of interleukin-2, interferon-alpha and tegafur uracil therapy for advanced renal cell cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Interferon alpha (Primary) ; Interleukin-2 (Primary) ; Tegafur/uracil (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms IATRCC
- 31 Mar 2016 Status changed from active, no longer recruiting to completed.
- 16 Sep 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by University Hospital Medical Information Network - Japan.
- 21 Jan 2014 Status changed from recruiting to active, no longer recruiting, according to University Hospital Medical Information Network (Japan) record.